Premium
Synthesis of Cycloruthenated Compounds as Potential Anticancer Agents
Author(s) -
Leyva Lida,
Sirlin Claude,
Rubio Laura,
Franco Cecilia,
Le Lagadec Ronan,
Spencer John,
Bischoff Pierre,
Gaiddon Christian,
Loeffler JeanPhilippe,
Pfeffer Michel
Publication year - 2007
Publication title -
european journal of inorganic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.667
H-Index - 136
eISSN - 1099-0682
pISSN - 1434-1948
DOI - 10.1002/ejic.200601149
Subject(s) - chemistry , denticity , decane , ruthenium , cisplatin , ligand (biochemistry) , cationic polymerization , stereochemistry , combinatorial chemistry , bipyridine , medicinal chemistry , organic chemistry , metal , crystal structure , catalysis , receptor , biochemistry , medicine , surgery , chemotherapy
A library of 19 cycloruthenated derivatives is constructed by making use of the well‐known cyclometalation reaction. Their geometries are modified in a straightforward manner by addition of either mono‐ or bidentate ligands, such as bipyridine, phenanthroline, 1,2‐bis(diphenylphosphanyl)ethane, dimethylphenylphosphane, triphenylphosphane, and 1,3,5‐triaza‐7‐phosphatricyclo[3.3.1.1]decane (PTA) ligands, to cationic cycloruthenated centers. The antitumor properties of the compounds thus obtained are investigated in order to compare them with recently reported ruthenium complexes and cisplatin. IC 50 values against mammalian cells (A‐172, HCT‐116, and RDM‐4) are determined for the library compounds and some of them, such as those derived from orthoruthenated phenylpyridine and a bidentate N,N ligand, display activity of the same order of magnitude as cisplatin. (© Wiley‐VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2007)